# DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

> **NCT02166905** · PHASE1,PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 40 (actual)

## Conditions studied

- Fallopian Tube Carcinoma
- Ovarian Carcinoma
- Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- **DRUG:** Epacadostat
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Poly ICLC

## Key facts

- **NCT ID:** NCT02166905
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-10
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-08-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166905, "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02166905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*